Oura Ring introduces advanced hormonal health tracking for Series 3 and 4 models
The wearable giant partners with Twentyeight Health to offer clinical consultations and expanded biometric analysis, though the features remain exclusive to its latest hardware.
Oura has announced a significant software update for its Series 3 and 4 smart rings, introducing enhanced hormonal health tracking capabilities that were previously unavailable on the platform. The update refines the existing Cycle Insights feature to explicitly account for over 20 combinations of hormonal birth control methods, including pills, patches, IUDs, and implants. By integrating data from these various methods, the system aims to gauge their impact on temperature patterns, sleep, recovery, and bleeding, providing users with personalised guidance during complex hormonal changes.
In a strategic move to bridge wearable data with clinical advice, Oura has partnered with the virtual health platform Twentyeight Health. This collaboration creates a dedicated portal within the Oura app where users can connect with licensed health providers to discuss birth control options and receive new prescriptions. The partnership is situated within the current United States legal landscape following the overturning of Roe v Wade, raising considerations regarding data privacy and the potential use of reproductive health information in legal proceedings.
A new Menopause Insights tool has also been added to the update, designed to track quality of life across 22 potential symptoms. The feature utilises longitudinal biometric data to provide a personalised questionnaire and on-demand explanations of results. Oura states that this functionality can deliver actionable insights to inform lifestyle changes, focusing on how physiological markers shift during the menopausal transition.
These specific hormonal health enhancements are exclusive to the Oura Ring 3 and Oura Ring 4. The company has confirmed that the features will not be available for the Oura Ring 2, marking a clear distinction in capabilities across its product line. The update is scheduled to launch globally on 6 May, allowing users of the latest hardware to access the expanded suite of health monitoring tools.
While the technology aims to track potential side effects of birth control and provide deeper context to biometric fluctuations, the specific accuracy of the new integration in predicting side effects has not yet been validated by independent clinical trials. Furthermore, the extent to which the Twentyeight Health provider portal will remain fully accessible and functional outside the United States is not explicitly detailed in the current announcement.
As the wearable technology market remains competitive, this update positions the Oura Ring 4 as a leading option for users seeking detailed health analytics. However, questions regarding user adoption rates for the new menopause questionnaire and the willingness of consumers to share sensitive reproductive data via the app remain unknown.
